A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new ...

At the moment, the only other approved medicine for SMA is Biogen’s blockbuster SMA treatment Spinraza (nusinersen), so it will be interesting to see if Zolgensma’s availability has impacted ...

Spinraza – approved in the US in 2016 and ... that may be a more convenient way of administration. Novartis’s Zolgensma (onasemnogene abeparvovec), approved in the US in 2019 and the EU ...

The arrival of Zolgensma was followed by a decline in Spinraza's sales during 2020, particularly in the US. Additional pressure was then placed on the brand when Roche launched its daily oral ...

Children with SMA given the gene therapy Zolgensma in infancy are maintaining motor milestones after up to 10 years, new ...

Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular ...

Patients can receive a single infusion of Zolgensma. The price of the drug was determined based on that for Spinraza, an existing drug. While Spinraza costs about 9.5 million yen per dosage and ...